SEC Form 4/A · accession 0001209191-15-085393
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Oct 22, 2015
Accepted (ET)
Dec 15, 2015 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $4.40 | Oct 22, 2015 | A | 28,572 | A | — | Oct 22, 2025 | Common Stock | 28,572 | 28,572 | D |
Explanation of responses
- F1The option grant was approved by Issuer's board of directors on October 22, 2015, subject to stockholder approval of an amendment of the Issuer's 2015 Stock Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on December 14, 2015.
- F2Award vests monthly over four (4) years starting September 1, 2015.